News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Canada OKs Schering-Plough Cancer Drug


Posted on: 02/02/2006

Canada OKs Schering-Plough Cancer Drug

Feb. 2, 2006, 12:33PM

© 2006 The Associated Press

KENILWORTH, N.J. — Schering-Plough Corp. said Thursday that Canadian regulators approved its Temodal cancer drug for use with radiation therapy in treating the most common type of brain tumor.

The drug, known generically as temozolomide and sold in the United States as Temodar, was approved for patients with glioblastoma multiforme, a form of malignant brain cancer. The drug was already sold in Canada to treat another type of brain tumor.

Schering-Plough said the therapy significantly extended the lives of study patients who took it together with radiation.

U.S. regulators approved temozolomide for glioblastoma multiforme in March.

Schering-Plough's shares rose a penny to $19.18 in midday trading on the New York Stock Exchange.

--------------------------------------------------------------------------------


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740